What question did this study set out to answer?

To assess the clinical implications and therapeutic outcomes of KRAS codon-specific mutations in advanced pancreatic ductal adenocarcinoma.

Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis evaluates KRAS mutations and clinical features in pancreatic cancer, suggesting implications for treatment outcomes.

To assess the clinical implications and therapeutic outcomes of KRAS codon-specific mutations in advanced pancreatic ductal adenocarcinoma.
Retrospective analysis of 269 advanced PDAC patients
Utilized next-generation sequencing for mutation detection
Evaluated clinical features, co-mutations, and treatment outcomes
KRAS mutations present in 92% of patients, predominantly G12V and G12D
TP53 co-mutation found in 67% of cases, enriched in G12D tumors
No significant survival differences among KRAS subtypes, except G12V shows longer survival with fluorouracil-based chemotherapy.

Cho et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis evaluates KRAS mutations and clinical features in pancreatic cancer, suggesting implications for treatment outcomes.